{"id":"monovalent-tetanus-vaccine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain or erythema"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Fever"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated tetanus toxin (toxoid) that triggers a humoral immune response, leading to the production of protective antibodies against tetanus toxin. Upon exposure to C. tetani, these pre-formed antibodies neutralize the bacterial toxin and prevent tetanus disease. Monovalent formulation contains only tetanus antigen, distinguishing it from combination vaccines.","oneSentence":"A monovalent tetanus toxoid vaccine that stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against Clostridium tetani infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:04.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Active immunization against tetanus"}]},"trialDetails":[{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00928785","phase":"PHASE3","title":"Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-07","conditions":"Healthy","enrollment":52},{"nctId":"NCT02094833","phase":"PHASE3","title":"DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":310},{"nctId":"NCT00345579","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4432},{"nctId":"NCT01125527","phase":"PHASE3","title":"Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Haemophilus Influenzae Type b (Hib) Infection","enrollment":700},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021},{"nctId":"NCT01947465","phase":"","title":"Immunogenicity and Safety of Vaccinations in Immunocompromised Persons","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2013-10","conditions":"Arthritis, Rheumatoid, Spondylarthritis, Vasculitis","enrollment":645},{"nctId":"NCT01044316","phase":"PHASE3","title":"Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-04","conditions":"Haemophilus Influenzae Type b (Hib) Infection","enrollment":670},{"nctId":"NCT01062477","phase":"PHASE3","title":"A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1056}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Monovalent Tetanus vaccine","genericName":"Monovalent Tetanus vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"A monovalent tetanus toxoid vaccine that stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against Clostridium tetani infection. Used for Active immunization against tetanus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}